SCHEMBL16142136

SCHEMBL16142136

C=CC(=O)OCCC(C)OC(=O)/C=C/I

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.44
HPGD P15428 1/20 0.43
ALDH1A1 P00352 4/20 0.43
TP53 P04637 3/20 0.43
HIF1A Q16665 3/20 0.43
CYP3A4 P08684 2/20 0.43
HSD17B10 Q99714 1/20 0.43
THRB P10828 2/20 0.37
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 2/20 0.32
LMNA P02545 1/20 0.32
CHRNB2 P17787 2/20 0.31
CHRNA4 P43681 2/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262349 0.88 TSHR (0.52) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL12266937 0.81 TSHR (0.48) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL31195682 0.81 TSHR (0.48) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL12112392 0.80 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL8565036 0.78 TSHR (0.57) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL12266941 0.78 ALOX15 (0.45) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL36638 0.78 TSHR (0.52) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL11684317 0.77 TSHR (0.44) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL15324203 0.77 TSHR (0.44) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL12770171 0.77 TSHR (0.43) TSHRHPGDALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802984-B2 Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases THE JOHNS HOPKINS UNIVERSITY (US) 2017-10-31 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2017-05-25 US disclosed
US-20160122390-A1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES THE JOHNS HOPKINS UNIVERSITY (US) 2016-05-05 US disclosed
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics THE JOHNS HOPKINS UNIVERSITY 2015-10-01 US disclosed
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122390-A1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES VEGFA, LRRFIP1, FLT1 TSHR 2524/4885HPGD 3420/4885ALDH1A1 3688/4885
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics DNMT3L, DBNL, HNRNPL TSHR 2581/4885HPGD 3928/4885ALDH1A1 2087/4885
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 TSHR 1764/4885HPGD 2480/4885ALDH1A1 883/4885
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 TSHR 1764/4885HPGD 2480/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.